• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

BupPractice

Buprenorphine Training

  • Train a Team
  • About
  • Contact
  • Log In

Waiver Training for NPs and PAs Part 1: Buprenorphine Training — Content

Current Status
Not Enrolled
Price
Closed
Get Started
This activity is currently closed

This activity has been archived and is no longer being maintained. You can find our currently offered activities via the homepage.

If you are in progress with this activity or would like assistance in any way, please contact us.

Review Activity Description

Activity Content

About Prescribing Buprenorphine
Course not enrolled
Impact of Opioid Use Disorder
Course not enrolled
Understanding Opioids Medications and Buprenorphine Formulations
Course not enrolled
Screening, Detection and Diagnosis of Opioid Use Disorder
Course not enrolled
Assessing Patients for Buprenorphine Treatment
Course not enrolled
Induction
Course not enrolled
Maintenance and Discontinuation
Course not enrolled
Pregnancy, Young Adults, Methadone Patients and Other Populations
Course not enrolled
Problematic Behaviors
Course not enrolled
Federal Laws and Regulations
Course not enrolled
Case: Chad Wright
Course not enrolled

Primary Sidebar

Activity Home
About Prescribing Buprenorphine
Impact of Opioid Use Disorder
Screening, Detection and Diagnosis of Opioid Use Disorder
Assessing Patients for Buprenorphine Treatment
Understanding Opioids Medications and Buprenorphine Formulations
Induction
Maintenance and Discontinuation
Pregnancy, Young Adults, Methadone Patients and Other Populations
Problematic Behaviors
Federal Laws and Regulations
Case: Chad Wright
Funding Information Development of this website was funded by grant #R44DA12066, contract #HHSN271200655304C, contracts #HHSN271200900003C and Grant #1R44DA027245-01, from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health. The website contents are solely the responsibility of the authors and do not necessarily represent the official views of NIDA. Ongoing development and maintenance is funded by the training fee and Clinical Tools, Inc. No commercial support is received.
Clinical Tools is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

  • Contact Us
  • Copyright & Reproduction Guidelines
  • Privacy Policy
  • Terms of Service
  • Technology Requirements
  • 508 Compliance

Footer

developed & maintained by
ClinicalTools

A member of The Clinical Encounters Training Group: SBIRT Training | BupPractice | PainTx Challenge | CE:Vaping | CE:Alcohol | CE:Obesity | OpioidCME

Clinical Tools, Inc. staff have disclosed no relevant financial relationships.

Unless otherwise noted, individuals pictured are models and are used for illustrative purposes only.
This site is for educational purposes only and medical decisions should not be based solely on its content. This site, its authors, and its consultants do not assume liability for errors or omissions.
  • Facebook
  • LinkedIn
  • Twitter
feedback@clinicaltools.com

101 A Market St Chapel Hill, NC 27516
919-960-8118

Contact us

© 2023 · Clinical Tools, Inc · Log in

  • Hidden
  • Hidden
  • Hidden
  • Your comments help guide other users & help us make improvements
  • Hidden
Buprenorphine Practice Gaps

Professional practice gaps exist when there is a disparity between educational needs and the ideal or desired level of knowledge, competence, and performance. Despite demonstrated effectiveness of buprenorphine (SAMHSA, 2020), only around 95,000 providers prescribe buprenorphine for office-based treatment of opioid use disorder, which is a small percentage considering that the pool of potential prescribers is well over a million (SAMHSA, 2021). Physicians, nurse practitioners, and physician assistants are likely to encounter patients having this disorder due to the size of the opioid epidemic:

  • 9.5 million people (3.4%) aged 12 or older engaged in misuse of opioids in 2020 (SAMHSA, 2021a). 
  • Many people who need treatment are still not receiving it; in 2019 only 18.1% of those needing it received medication-assisted treatment for opioid use disorder (SAMHSA, 2020a).
  • Practitioners having a DEA registration to prescribe controlled substances can prescribe buprenorphine for opioid use disorder and detoxification (HHS, 2021). Federal law requires practitioners wishing to see more than 30 patients to complete an 8-hour certification training in order to prescribe buprenorphine (SAMHSA, 2020b; HHS, 2021).
  • This training is intended for practitioners who are not required to complete a certification training for a waiver and others who wish to refresh skills or learn more about buprenorphine.

Buprenorphine is a safe and effective treatment for opioid use disorder. Until the exemption for practitioners with DEA registration announced on April 28, 2021 (HHS, 2021), 8 hours of training by an approved organization was required by law in order to prescribe it (SAMHSA, 2020b). Providing information on all aspects of buprenorphine treatment will help address this knowledge need. Moreover, buprenorphine treatment has a protocol for successful outcomes and to minimize risks of overdose, death, and diversion (ASAM, 2020), which validates a need for training for many providers. New, extended-release formulations of buprenorphine have been released over the past several years, resulting in the need to learn new clinic protocols and understanding of patient needs (Compton & Volkow, 2021).

Understanding of clinical protocol and how to apply it will help address this competence need. Experience with interactive case scenarios helps address the performance need of translating competence in following the protocol into actual practice. 

Practice Gap References

ASAM. The ASAM National Practice Guideline For the Treatment of Opioid Use Disorder 2020 Focused Update. 2020.

Compton W & Volkow N. Extended-Release Buprenorphine and Its Evaluation With Patient-Reported Outcomes. JAMA Netw Open. 2021;4(5):e219708. doi:10.1001/jamanetworkopen.2021.9708

Health and Human Services Department. Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. Fed Regist. April 28, 2021.

Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.; 2020a.

Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.; 2021a.

SAMHSA. Buprenorphine. October 7, 2020b.

SAMHSA. Practitioner and Program Data. SAMHSA.gov. 2021b.

Participation Requirements

Activity Credit: Obtaining credit for participation in this activity requires that you complete the pre-assessments, work through the modules (including all in-module interactive activities), complete the post-assessments with a 70% score on the post-test, and then request credit. At the end of the activity, you will be instructed on how to print out a certificate for your records.

Time Requirement: Keep track of the amount of time it takes you to complete this activity. You will be required to spend a set amount of time in order to claim credit. You should claim credit only for the time actually spent in the activity.

Technical Requirement:Our site requires the latest versions of Google Chrome, Safari, Firefox, or Microsoft Edge. The site is not optimized for Internet Explorer and certain functionality will not work with that browser. Please utilize a supported browser when accessing the site.

Login

Forgot Password?
Register New Account

Registration

  • Hidden
  • If you already have an account on one of our other Clinical Encounters sites, you do not need to create a new account, simply log in.
  • Hidden
  • Hidden
  • By registering, you agree to the Terms of Service and Privacy Policy. If you are a part of a group, you understand your participation information can be provided to the group organizer.
  • This field is for validation purposes and should be left unchanged.